Study: NCT02763839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 25/100
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 25/100
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 25/100
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 25/100
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet 25/100
Description: Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp \& Dohme) tablets; oral route.